Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
In the register
The register attaches this trial to Delgocitinib (LEO 124249) (LEO Pharma), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Terminated early
- Declared phase
- Phase 2
- Sponsor
- LEO Pharma
- Participants (registry)
- 13
- Start
- October 2017
- Primary completion
- May 2018
- Study completion
- May 2018
- Last registry update
- February 2025
- Countries
- Denmark
Conditions studied: Alopecia Areata
Interventions: LEO 124249, Ointment vehicle
Other trials of Delgocitinib (LEO 124249)
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
LEO 124249 Ointment in the Treatment of Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.